ESLC:F:F-ESSILORLUXOTTICA 1/2/O.N. (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 102

Change

-1.00 (-0.97)%

Market Cap

USD 95.93B

Volume

4.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-17 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

N/A

USD 141.14B
ESL:F EssilorLuxottica Société ano..

N/A

USD 94.21B
BOX:F Becton Dickinson and Company

N/A

USD 62.42B
HYB0:F HOYA CORP. ADR/ 1 O.N.

N/A

USD 39.34B
HYB:F HOYA Corporation

N/A

USD 38.54B
RMEA:F Resmed Inc DRC

N/A

USD 29.01B
RME:F ResMed Inc

N/A

USD 28.97B
CBHD:F Coloplast A/S

N/A

USD 25.77B
CBH:F COLOPLAST SP.ADR 1/10 DK1

N/A

USD 25.37B
TUO:F Terumo Corporation

N/A

USD 23.10B

ETFs Containing ESLC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.97% 80% B- 72% C
Dividend Return 2.36% 73% C 51% F
Total Return 16.32% 74% C 69% C-
Trailing 12 Months  
Capital Gain 10.87% 80% B- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.87% 72% C 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.77% 65% D 60% D-
Dividend Return 3.77% 59% D- 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.87% 87% B+ 88% B+
Risk Adjusted Return 47.85% 82% B 74% C
Market Capitalization 95.93B 99% N/A 98% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.